Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669810 | 0.86 | GABRP (0.49) | POLBLMNAMAPTTDP1NHERF1 | |
| SCHEMBL6670721 | 0.84 | NHERF1 (0.55) | POLBLMNAMAPTTDP1SMN1; SMN2 | |
| SCHEMBL7834823 | 0.78 | NHERF1 (0.60) | POLBMAPTTDP1NPC1RAB9A | |
| SCHEMBL7834337 | 0.78 | KDM4E (0.49) | POLBMAPTTDP1SMN1; SMN2 | |
| SCHEMBL7842334 | 0.77 | NHERF1 (0.58) | POLBLMNAMAPTTDP1SMN1; SMN2 | |
| SCHEMBL6818435 | 0.76 | POLB (0.67) | POLBLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6698592 | 0.74 | — | — | |
| SCHEMBL7842187 | 0.74 | CFTR (0.42) | POLBLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6205703 | 0.74 | NHERF1 (0.63) | POLBLMNAMAPTTDP1SMN1; SMN2 | |
| SCHEMBL6230550 | 0.73 | NHERF1 (0.68) | POLBMAPTTDP1SMN1; SMN2NHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004019932-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1140850-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040561-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| EP-1140850-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040561-A1 | QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-13 | — | — | WO | disclosed |